Abacus Planning Group Inc. Invests $99,000 in Organon & Co. $OGN

Abacus Planning Group Inc. purchased a new position in shares of Organon & Co. (NYSE:OGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,232 shares of the company’s stock, valued at approximately $99,000.

Several other large investors have also recently added to or reduced their stakes in the company. Ransom Advisory Ltd acquired a new position in Organon & Co. during the 1st quarter worth approximately $32,000. Hanson & Doremus Investment Management purchased a new stake in shares of Organon & Co. in the second quarter valued at approximately $26,000. Brooklyn Investment Group boosted its stake in shares of Organon & Co. by 1,012.3% in the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after buying an additional 2,794 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Organon & Co. during the first quarter worth $51,000. Finally, PARK CIRCLE Co raised its position in Organon & Co. by 640.7% in the first quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock worth $60,000 after acquiring an additional 3,460 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

OGN opened at $11.03 on Friday. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $19.05. The stock has a market cap of $2.87 billion, a P/E ratio of 4.10, a P/E/G ratio of 1.00 and a beta of 0.63. The stock’s 50 day simple moving average is $9.86 and its 200 day simple moving average is $10.41. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.Organon & Co.’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Organon & Co.’s dividend payout ratio is presently 2.97%.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.